Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-07-03
2007-07-03
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024100, C536S024500, C435S375000, C435S377000
Reexamination Certificate
active
10719633
ABSTRACT:
The invention relates to compositions comprising oligomers antisense to bacterial 16S or 23S rRNA and capable of selectively modulating the biological activity thereof, and methods for their use. More particularly, the invention relates to antisense oligomers directed to 16S or 23S rRNA found in one or more particular bacteria, or generally conserved among bacteria in general, and to pharmaceutical compositions and methods of treatment comprising the same.
REFERENCES:
patent: 5220014 (1993-06-01), Ackerman et al.
patent: 5821052 (1998-10-01), Chen et al.
patent: 5977340 (1999-11-01), Colote et al.
patent: 6060456 (2000-05-01), Arnold et al.
patent: 6133246 (2000-10-01), McKay et al.
patent: 6228579 (2001-05-01), Zyskind et al.
patent: 6239265 (2001-05-01), Cook
patent: 6495663 (2002-12-01), Rothbard
patent: 6677153 (2004-01-01), Iversen
patent: 7049431 (2006-05-01), Iversen
patent: 0 894 857 (1998-07-01), None
patent: 0 892 064 (1998-09-01), None
patent: WO 91 09033 (1991-06-01), None
patent: WO 98/03533 (1998-01-01), None
patent: WO 98/32467 (1998-07-01), None
patent: WO 99/02673 (1999-01-01), None
Agrawal et al.,Tibtech, 14:376-387 (1996).
Baker, Pamela J. et al., “Subinhibitory Concentrations of Cefpodoxime Alter Membrane Protein Expression ofActinobacillus actinomycetemcomitansand Enhance Its Susceptibility to Killing by Neutrophils”, Antimicrobial Agents and Chemotherapy, pp. 406-412, Feb. 1995.
Branch et al.,Trends in Biochem. Sci., 23:45-50 (1998).
Filadoro, F., “Bacteria, Antibiotics and the Immune System: A Look at a Classic Triad”, Igiene Moderna 104(3), pp. 459-465, 1995 (Abstract Only).
Green et al.,J. Am. Coll. Surg., Collective Review, pp. 93-105.
Good et al.,Nature Biotechnology, 16:355-358 (1998).
Good et al.,PNAS, 95:2073-2076 (1998).
Gotfried et al.,Clinical Therapeutics, 22(1):2-14 (2000).
Iversen, Patrick L., “Phosphorodiamidate Morpholino Oligomers”, Antisense Drug Technology, Principles, Strategies and Applications, Copyright 2001 by Marcel Dekker, Inc., pp. 375-389.
Jayaraman et al.,PNAS, 78(3):1537-1541 (1981).
Jen et al.,Stem Cells, 18:307-319 (2000).
Rahman et al.,Antisense Research and Development, 1:319-327 (1991).
Suzuki, I. et al., “In vivo Activity of Cefbuperazone (T-1982) Against Various Experimental Infections in Mice”, Journal of Antibiotics (J. Antibiot.) (Japan) 38/2, pp. 249-258, 1985 (Abstract Only).
Summerton et al.,Biochim et. Biophys. ACTA, 1489:141-158 (1999).
Tornqvist, Inga Odenholt et al., “Pharmacodynamic Effects of Subinhibitory Antibiotic Concentrations”, Scand J. Infect Dis, Suppl. 74:94-101, 1991.
Zak, O. et al., “Correlation of Antibacterial Activities of Antibiotics in vitro and in Animal Models of Infection”, Journal of Antimicrobial Chemotherapy 15, Suppl. A, pp. 273-282, 1985.
AVI BioPharma Inc.
McGarry Sean
Perkins Coie LLP
LandOfFree
Antisense antibacterial method and composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense antibacterial method and composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense antibacterial method and composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3820524